Incomplete dominance of type III hyperlipoproteinemia is associated with the rare apolipoprotein E2 (Arg136 → Ser) variant in multigenerational pedigree studies

Atherosclerosis

Volumn 122, Issue 1, 1996, Pages 33-46

  Pocovi, M ^a   Cenarro, A ^a   Civeira, F ^a   Myers, R H ^b   Casao, E ^a   Esteban, M ^a   Ordovas, J M ^c  

^a UNIVERSITY OF ZARAGOZA   (Spain)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c TUFTS UNIVERSITY   (United States)

Author keywords

Apolipoprotein E; Genetics; Hyperlipoproteinemia; Lipoproteins

Indexed keywords

APOLIPOPROTEIN E2;

ARTICLE; BODY MASS; CLINICAL ARTICLE; FAMILY STUDY; FEMALE; GENETICS; HUMAN; HYPERLIPOPROTEINEMIA; MALE; MUTATION; PEDIGREE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

EID: 0029978151     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/0021-9150(95)06745-0     Document Type: Article

References (48)

1. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science 1986;232:34.
2. Davignon J, Gregg RE, Sing CF. Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis 1988;8:1.
3. Sing CF, Davignon J. Role of the apolipoprotein E polymorphism in determining normal plasma lipid and lipoprotein variation. Am J Hum Genet 1985;37:268.
4. Schaefer EJ, Lamon-Fava S, Johnson S et al. Effects of gender and menopausal status on the association of apolipoprotein E phenotype with plasma lipoprotein levels. Arterioscler Thromb 1994;14:1105.
5. Eto M, Watanabe K, Makino I. Increased frequencies of apolipoprotein E2 and E4 alleles in patients with ischemic heart disease. Clin Genet 1989;13112:253.
6. Van Bockxmeer FM, Mamotte CDS. Apolipoprotein ∈4 homozygosity in young men with coronary heart disease. Lancet 1992;340:879.
7. Kuusi T, Nieminen MS, Ehnholm C et al. Apolipoprotein E polymorphism and coronary artery disease. Increased prevalence of apolipoprotein E-4 in angiographically verified coronary patients. Arteriosclerosis 1989;9:237.
8. Nieminen MS, Mattila KJ, Aalto-Setälä K et al. Lipoproteins and their genetic variation in subjects with and without angiographically verified coronary artery disease. Arterioscler Thromb 1992;12:58.
9. Utermann G, Hardewig A, Zimmer F. Apolipoprotein E phenotypes in patients with myocardial infarction. Hum Genet 1984;65:237.
10. Stuyt PMJ, Brenninkmeijer BJ, Demacker PNM et al. Apolipoprotein E phenotypes, serum lipoproteins and apolipoproteins in angiographically assessed coronary heart disease. Scand J Clin Lab Invest 1991;51:425.
11. Menzel HJ, Kladetzky RG, Assmann G. Apolipoprotein E polymorphism and coronary artery disease. Arteriosclerosis 1983;3:310.
12. Eichner JE, Kuller LH, Orchard TJ et al. Relation of apolipoprotein E phenotype to myocardial infarction and mortality from coronary artery disease. Am J Cardiol 1993;71:160.
13. Lenzen HJ, Assmann G, Buchwalsky R, Schulte H. Association of Apolipoprotein E polymorphism, low-density lipoprotein cholesterol, and coronary artery disease. Clin Chem 1986;32:778.
14. Hixson JE, PDAY. Research Group, Apolipoprotein E polymorphisms affect atherosclerosis in young males. Arterioscler Thromb 1991;11:1237.
15. Wilson PWF, Myers RH, Larson MG, Ordovas JM, Wolf PA, Schaefer EJ. Apolipoprotein E alleles, dyslipidemia, and coronary heart disease: The Framingham Offspring Study. J Am Med Assoc 1994;272:1666.
16. Choi SY, Cooper AD. A comparison of the roles of the low density lipoprotein (LDL) receptor and the LDL receptor-related protein/α2-macroglobulin receptor in chylomicron remnant removal in the mouse in vivo. J Biol Chem 1993;268:15804.
17. Beisiegel U, Weber W, Ihrke G, Herz J, Stanley KK. The LDL-receptor-related protein, LRP, is an apolipoprotein E-binding protein. Nature 1989;341:162.
18. Zannis VI, Breslow JL. Human very low density lipoprotein apolipoprotein E isoprotein polymorphism is explained by genetic variation and posttranslational modification. Biochemistry 1981;20:1033.
19. Weisgraber KH, Rail SC Jr., Mahley RW. Human E apoprotein heterogeneity. J Biol Chem 1981;256:9077.
20. Gregg RE, Zech LA, Schaefer EJ, Stark D, Wilson D, Brewer HB, Jr. Abnormal in vivo metabolism of apolipoprotein E4 in humans. J Clin Invest 1986;78:815.
21. Utermann G, Hees M, Steinmetz A. Polymorphism of apolipoprotein E and occurrence of dysbetalipoproteinaemia in man. Nature 1977;269:604.
22. Rall SC Jr., Weisgraber KH, Innerarity TL, Mahley RW. Structural basis for receptor binding heterogeneity of apolipoprotein E from type III hyperlipoproteinemic subjects. Proc Natl Acad Sci USA 1982;79:4696.
23. Rall SC Jr., Weisgraber KH, Innerarity TL, Bersot TP, Mahley RW. Identification of a new structural variant of human apolipoprotein E, E2(Lysl46-Gln), in a type III hyperlipoproteinemic subject with the E3/2 phenotype. J Clin Invest 1983;72:1288.
24. Wardell MR, Brennan SO, Janus ED, Fraser R, Carrel RW. Apolipoprotein E2-Christchurch (136 Arg-Ser). New variant of human apolipoprotein E in a patient with type III hyperlipoproteinemia. J Clin Invest 1987;80:253.
25. Walden CC, Huff MW, Leiter LA, Connelly PW, Hegele RA. Detection of a new apolipoprotein-E mutation in type III hyperlipidemia using deoxyribonucleic acid restriction isotyping. J Clin Endocrinol Metab 1994;78:699.
26. Moriyama K, Sasaki J, Matsunaga A et al. Apolipoprotein E1 Lys-146→Glu with type III hyperlipoproteinemia. Biochim Biophys Acta Lipids Lipid Metab 1992;1128:58.
27. Feussner G, Funke H, Weng W, Assmann G, Lackner KJ, Ziegler R. Severe type III hyperlipoproteinemia associated with unusual apolipoprotein E1 phenotype and ∈1/'null' genotype. Eur J Clin Invest 1992;22:599.
28. 158→Cys) variant. Klin Wochenschr 1992;70:614.
29. Wenham PR, McDowell IFW, Hodges VM et al. Rare apolipoprotein E variant identified in a patient with Type III hyperlipidaemia. Atherosclerosis 1993;99:261.
30. Horie Y, Fazio S, Westerlund JR, Weisgraber KH, Rail SC Jr. The functional characteristics of a human apolipoprotein E variant (cysteine at residue 142) may explain its association with dominant expression of type III hyperlipoproteinemia. J Biol Chem 1992;267:1962.
31. de Knijff P, van den Maagdenberg AMJM, Stalenhoef AFH et al. Familial dysbetalipoproteinemia associated with apolipoprotein E3-Leiden in an extended multigeneration pedigree. J Clin Invest 1991;88:643.
32. Fazio S, Horie Y, Weisgraber KH, Havekes LM, Rail SC Jr. Preferential association of apolipoprotein E Leiden with very low density lipoproteins of human plasma. J Lipid Res 1993;34:447.
33. 145 → Cys) is associated with incomplete dominance of type III hyperlipoproteinemia. J Biol Chem 1992;267:13642.
34. Lohse P, Mann A, Stein EA, Brewer HB. Apolipoprotein E-4 Philadelphia (Glu13-Lys, Arg145-Cys). J Biol Chem 1991;266:10479.
35. Schaefer EJ, Gregg RE, Ghiselli G et al. Familial apolipoprotein E deficiency. J Clin Invest 1986;78:1206.
36. Lohse P, Brewer HB III, Meng MS, Skarlatos SI, Larosa JC, Brewer HB Jr. Familial apolipoprotein E deficiency and type III hyperlipoproteinemia due to a premature stop codon in the apolipoprotein E gene. J Lipid Res 1992;33:1583.
37. Ji Z-S, Fazio S, Mahley RW. Variable heparan sulfate proteoglycan binding of apolipoprotein E variants may modulate the expression of type III hyperlipoproteinemia. J Biol Chem 1994;269:13421.
38. Moreda A, Alamillo JA, Pocovi M, Civeira F, Blasco M, Ordovas JM. Lipid levels and lipoprotein distribution in a Spanish working population. Clin Invest Arterioscl 1990;2:48.
39. Ordovas JM, Litwack-Klein L, Wilson PWF, Schaefer MM, Schaefer, EJ. Apolipoprotein E isoform phenotyping methodology and population frequency with identification of apo E1 and apo E5 isoforms. J Lipid Res 1987;28:371.
40. Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 1990;31:545.
41. Lathrop GM, Ott J, Lalouel JM, Julien C. Strategies for multilocus linkage analysis in humans. Proc Natl Acad Sci USA 1984;81:3443.
42. Emi M, Wu LL, Robertson MA et al. Genotyping and sequence analysis of apolipoprotein E isoforms. Genomics 1988;3:373.
43. Feussner G, Albanese M, Valencia A, Schuster H. Apolipoprotein E2Heidelberg (arg136 → Cys), a new variant of apolipoprotein E associated with incomplete dominance of type III hyperlipidemia. Atherosclerosis 1994;109:261.
44. 136 → His): Association with mild dyslipidemia and double pre-β very low density lipoproteins. J Lipid Res 1995;36:57.
45. Cooper DN, Krawczak M. The mutational spectrum of single base-pair substitutions causing human genetic disease: patterns and predictions. Hum Genet 1990;85:55.
46. Weisgraber KH, Innerarity TL, Harder KJ et al. The receptor binding domain of human apolipoprotein E. Monoclonal antibody inhibition of binding. J Biol Chem 1983;258:12348.
47. Lalazar A, Weisgraber KH, Rall SC et al. Site-specific mutagenesis of human apolipoprotein E. Receptor binding activity of variants with single amino acid substitutions. J Biol Chem 1988;263:3542.
48. Yang Y-W, Chan L, Li W-H. Cloning and sequencing of bovine apolipoprotein E complementary DNA and molecular evolution of apolipoproteins E, C-I, and C-II. J Mol Evol 1991;32:469.